# COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells

> **NCT04402892** · NA · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **OTHER:** 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )
- **OTHER:** 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)

## Key facts

- **NCT ID:** NCT04402892
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402892, "COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04402892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*